Primary Cicatricial Alopecias

    April 2010 in “ Expert Review of Dermatology
    Adel Alsantali, Jerry Shapiro
    Image of study
    TLDR The document concludes that early diagnosis and treatment are crucial for managing rare hair loss disorders and that more research is needed to improve treatment strategies.
    The document from April 2010 provides a comprehensive review of primary cicatricial alopecias (PCAs), a group of rare inflammatory disorders that result in permanent hair follicle destruction and irreversible hair loss. It categorizes PCAs into lymphocytic, neutrophilic, and mixed types, with specific conditions such as discoid lupus erythematosus (DLE) and lichen planopilaris (LPP) being discussed in detail, including their clinical features, etiology, and treatment options. The article also covers other PCAs like frontal fibrosing alopecia (FFA), pseudopelade of Brocq (PPB), central centrifugal cicatricial alopecia (CCCA), alopecia mucinosa (AM), keratosis follicularis spinulosa decalvans (KFSD), and folliculitis decalvans (FD), providing insights into their presentation and management. The importance of early diagnosis and intervention is emphasized to prevent further hair loss, and the need for controlled clinical trials to evaluate therapeutic options is highlighted, along with the potential for technological advances to improve PCA management strategies.
    Discuss this study in the Community →

    Research cited in this study

    31 / 31 results

    Related Community Posts Join

    6 / 289 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 4 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  119 upvotes 6 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Similar Research

    5 / 1000+ results